LX-2006 is under clinical development by LEXEO Therapeutics and currently in Phase II for Cardiomyopathy. According to GlobalData, Phase II drugs for Cardiomyopathy have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-2006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LX-2006 overview

LX-2006 is under development for the treatment of cardiomyopathy associated with Friedreich’s Ataxia. The drug candidate consists of Adeno-associated virus (AAV) vector carrying frataxin gene and is administered through intravenous route.

LEXEO Therapeutics overview

LEXEO Therapeutics, is a gene therapy company focused on rare and non-rare monogenic (single gene mutation) diseases. The company is headquartered in United States.

For a complete picture of LX-2006’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.